In the realm of infectious diseases, the management of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) poses a significant challenge to healthcare providers. Dalbavancin, a long-acting lipoglycopeptide antibiotic, has emerged as a promising option in the treatment of ABSSSIs in adults. This article aimed at exploring the prescriptive appropriateness of dalbavancin by adopting an integrated approach which considered clinical profile, patient-and health system-related factors, and environmental impact.
Clinical profile: efficacy and safetyDalbavancin's pharmacokinetic characteristics, including its prolonged half-life, allow for a weekly dosing schedule, which could be seen as convenient. Its effectiveness against a range of Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), suggests it might be a viable treatment option (Monteagudo-Martıńez et al., 2022). Clinical studies have indicated success rates for dalbavancin between 80% and 98%, comparable to standard treatments (Simonetti et al., 2021;Oliva et al., 2023). Evaluating dalbavancin's safety is also important, although adverse events have been infrequently reported in the literature, underscoring the importance of ongoing monitoring for any Frontiers in Antibiotics frontiersin.org 01